Smartlab Europe

Agilent Technologies and Oxford Gene Technology Expand Microarray and Sequencing Partnership

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...
- Advertisement -

Agilent Technologies Inc. and Oxford Gene Technology today announced they have expanded an existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays and SureSelect target enrichment products for next-generation sequencing.

Mike Evans, chief executive of OGT, said: “We are delighted to have been able to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”

“Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program,” said Robert Schueren, vice president and general manager of Agilent’s genomics business. “OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”

Latest stories

Related stories

Lilly Launches New AI Supercomputer for Drug Development

Eli Lilly has launched what it describes as the...

Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions

Periodontal disease has long been viewed primarily as a...

How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility

In 2026, the Pharmaceutical and Medical Device sectors face...

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Novo Nordisk and Vivtex have formalised a collaboration aimed...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »